Kenvue’s stock slides premarket as company reports slow start to flu and cold season

México Noticias Noticias

Kenvue’s stock slides premarket as company reports slow start to flu and cold season
México Últimas Noticias,México Titulares
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Kenvue Inc.’s stock KVUE, -1.25% fell 2.4% in premarket trade Thursday, after the company posted in-line third-quarter earnings but tightened its full-year guidance after a slow start to the flu and cold season. The company, the former consumer health operations of Johnson & Johnson JNJ, +0.22%, posted net income of $438 million, or 23 cents a share, for the quarter, down from $586 million, or 34 cents a share, in the year-earlier period.

789 billion a year ago, while FactSet expected $3.906 billion. The company is now expecting the strong dollar to present a headwind to full-year sales of about 1 to 2 percentage points, up from one percentage point previously expected. “Reflecting a softer than anticipated start to the cough, cold and flu season and increased impact of foreign exchange,” the company tightened its net sales outlook for fiscal 2023 to 4.0% to 4.5%. It expects adjusted EPS of $.26 to $1.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

MarketWatch /  🏆 3. in US

México Últimas Noticias, México Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Kimberly-Clark posts better -than-expected profit but sales fall slightly shortKimberly-Clark posts better -than-expected profit but sales fall slightly shortCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »

AstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccineAstraZeneca said U.S. FDA has accepted for review its Flumist self-administered flu vaccineCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »

Stellantis and Orano to enter joint venture for recycling EV batteries and scrap from gigafactoriesStellantis and Orano to enter joint venture for recycling EV batteries and scrap from gigafactoriesCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »

Overstock to rename itself Beyond Inc. from Nov. 6 and switch listing to NYSE under new ticker ‘BYON’Overstock to rename itself Beyond Inc. from Nov. 6 and switch listing to NYSE under new ticker ‘BYON’Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »

Teladoc’s stock tumbles after-hours after company misses sales estimates and offers soft guidanceTeladoc’s stock tumbles after-hours after company misses sales estimates and offers soft guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »

Usana Health’s stock dips then turns flat after earnings miss and lowered guidanceUsana Health’s stock dips then turns flat after earnings miss and lowered guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Leer más »



Render Time: 2025-02-27 03:40:50